173 related articles for article (PubMed ID: 22076913)
1. Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis.
Irazabal MV; Eirin A; Gertz MA; Dispenzieri A; Kumar S; Buadi FK; Lacy MQ; Hayman SR; Dingli D; Hogan WJ; Gastineau DA; Glavey SV; Amer H; Leung N
Am J Hematol; 2012 Jan; 87(1):51-4. PubMed ID: 22076913
[TBL] [Abstract][Full Text] [Related]
2. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.
Leung N; Kumar SK; Glavey SV; Dispenzieri A; Lacy MQ; Buadi FK; Hayman SR; Dingli D; Kapoor P; Zeldenrust SR; Russell SJ; Lust JA; Hogan WJ; Rajkumar SV; Gastineau DA; Kourelis TV; Lin Y; Gonsalves WI; Go RS; Gertz MA
Nephrol Dial Transplant; 2016 Aug; 31(8):1284-9. PubMed ID: 26627634
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation.
Herrmann SM; Gertz MA; Stegall MD; Dispenzieri A; Cosio FC; Kumar S; Lacy MQ; Dean PG; Prieto M; Zeldenrust SR; Buadi FK; Russell SJ; Nyberg SL; Hayman SR; Dingli D; Fervenza FC; Leung N
Nephrol Dial Transplant; 2011 Jun; 26(6):2032-6. PubMed ID: 21543655
[TBL] [Abstract][Full Text] [Related]
4. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
Leung N; Dispenzieri A; Lacy MQ; Kumar SK; Hayman SR; Fervenza FC; Cha SS; Gertz MA
Clin J Am Soc Nephrol; 2007 May; 2(3):440-4. PubMed ID: 17699449
[TBL] [Abstract][Full Text] [Related]
5. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
[TBL] [Abstract][Full Text] [Related]
8. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
Bergesio F; Ciciani AM; Manganaro M; Palladini G; Santostefano M; Brugnano R; Di Palma AM; Gallo M; Rosati A; Tosi PL; Salvadori M;
Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
[TBL] [Abstract][Full Text] [Related]
9. High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis.
Kumar S; Dispenzieri A; Lacy MQ; Litzow MR; Gertz MA
Bone Marrow Transplant; 2001 Aug; 28(4):381-5. PubMed ID: 11571511
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantation.
Jimenez-Zepeda VH; Trudel S; Reece DE; Chen C; Rabea AM; Kukreti V
Am J Hematol; 2011 Oct; 86(10):873-5. PubMed ID: 21815185
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome.
Mollee PN; Wechalekar AD; Pereira DL; Franke N; Reece D; Chen C; Stewart AK
Bone Marrow Transplant; 2004 Feb; 33(3):271-7. PubMed ID: 14647248
[TBL] [Abstract][Full Text] [Related]
12. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of Engraftment Syndrome following Autologous Stem Cell Transplantation in Light Chain Amyloidosis with Renal Involvement.
Miao F; Ren G; Guo J; Zhao L; Xu W; Huang X
Transplant Cell Ther; 2023 Feb; 29(2):110.e1-110.e8. PubMed ID: 36323398
[TBL] [Abstract][Full Text] [Related]
14. Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.
Roth RM; Benson D; Hebert LA; Bissell MG; Satoskar AA; Nadasdy T; Brodsky SV
Arch Pathol Lab Med; 2013 Sep; 137(9):1304-8. PubMed ID: 23991744
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.
Oran B; Malek K; Sanchorawala V; Wright DG; Quillen K; Finn KT; La Valley M; Skinner M; Seldin DC
Bone Marrow Transplant; 2005 Mar; 35(6):567-75. PubMed ID: 15665842
[TBL] [Abstract][Full Text] [Related]
16. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
17. Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria.
Maiolino A; Biasoli I; Lima J; Portugal AC; Pulcheri W; Nucci M
Bone Marrow Transplant; 2003 Mar; 31(5):393-7. PubMed ID: 12634731
[TBL] [Abstract][Full Text] [Related]
18. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney.
Eirin A; Irazabal MV; Gertz MA; Dispenzieri A; Lacy MQ; Kumar S; Sethi S; Nasr SH; Cornell LD; Fidler ME; Fervenza FC; Leung N
Nephrol Dial Transplant; 2012 Mar; 27(3):1097-101. PubMed ID: 22067518
[TBL] [Abstract][Full Text] [Related]
19. Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival.
Gorak E; Geller N; Srinivasan R; Espinoza-Delgado I; Donohue T; Barrett AJ; Suffredini A; Childs R
Biol Blood Marrow Transplant; 2005 Jul; 11(7):542-50. PubMed ID: 15983554
[TBL] [Abstract][Full Text] [Related]
20. Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome.
Koreth J; Biernacki M; Aldridge J; Kim HT; Alyea EP; Armand P; Cutler C; Ho VT; Wu CJ; Antin JH; Soiffer RJ
Biol Blood Marrow Transplant; 2011 Mar; 17(3):421-8. PubMed ID: 20870027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
